I have stated on many an occasion that I saw the immediate advancement of this company in the Carotid area i.e. CAE. The VascuCel product should do this and with little additional personnel cost as the same reps who service CC work will do the same for the CAE product. I do wish that the company might strike a deal with China to service the paediatric CC area which due to population numbers is vast.
AHZ, page-173
-
- There are more pages in this discussion • 139 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$10.26 |
Change
0.060(0.59%) |
Mkt cap ! $218.2M | |||
| Open | High | Low | Value | Volume |
| $10.50 | $10.50 | $10.06 | $58.65K | 5.718K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 975 | $10.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $10.28 | 352 | 3 |
View Market Depth
| Last trade - 14.52pm 04/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |